Shares of Sanofi slumped on Monday as the French drugmaker said a U.S. regulatory review of its multiple-sclerosis drug won’t ...

Shares of French pharmaceutical group Sanofi fell 4% on Monday after it flagged another delay to a U.S. regulatory decision ...

Results from the PERSEUS Phase III study showed that tolebrutinib did not meet its primary endpoint in delaying time to ...

Sanofi shares slide after FDA delays review of its MS drug tolebrutinib and a late-stage trial fails to meet its main goal.

NEW YORK, Jan. 26, 2023 (GLOBE NEWSWIRE) -- TG Therapeutics, Inc. (TGTX) today announced the commercial launch of BRIUMVI™ (ublituximab-xiiy), for the treatment of relapsing forms of multiple ...

MENLO PARK, Calif.--(BUSINESS WIRE)--Octave, a leading digital health sciences company that delivers a new standard for managing multiple sclerosis (MS) and other neurodegenerative diseases, today ...

HIGH POINT, N.C.--(BUSINESS WIRE)--Banner Life Sciences LLC (Banner), a privately held specialty pharmaceutical company, today announced that BAFIERTAM™ (monomethyl fumarate), a novel fumarate for ...

Tolebrutinib received provisional approval in the United Arab Emirates in July 2025 for non-relapsing secondary progressive ...

Partial sales of TG Therapeutics, Inc.'s BRIUMVI for Relapsing forms of multiple sclerosis reached $7.8 million in Q1 of 2023. In June 2023, TG Therapeutics received European approval of BRIUMVI for ...

Octave Bioscience, a commercial-stage precision care company pioneering a new standard for managing multiple sclerosis (MS) and other neurodegenerative diseases such as Parkinson's disease, today ...

ROCHESTER, NY, May 2, 2024 – Empire Discovery Institute (EDI) has entered into a collaborative research partnership with the National Multiple Sclerosis Society and its commercial development program ...